CAI Caris Life Sciences, Inc.
Stock · NasdaqGS · United States · Healthcare · US1421521071
NowoTrade is an independent information site. It is not affiliated with, endorsed by or sponsored by Caris Life Sciences, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD.
Updated 07 Nov 2026 09:54. Information, not advice.
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 25 Feb 2027 16:00 | 0.11 | — | — | Upcoming |
| 04 Nov 2026 16:00 | 0.02 | 0.05 | +148.5% | Beat |
| 05 Aug 2026 16:00 | 0.01 | — | -100.0% | — |
| 07 May 2026 16:00 | -0.02 | — | +100.0% | — |
| 26 Feb 2026 16:00 | 0.10 | 0.28 | +168.7% | Beat |
| 05 Nov 2025 16:00 | -0.14 | 0.08 | +158.8% | Beat |
| 12 Aug 2025 16:00 | -0.22 | -1.11 | -411.2% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 812M | +97.0% | -68.1M | -8.4% | -3.22 | -136.6% | 66.9M |
| 2024 | 412.3M | +34.7% | -281.9M | -68.4% | -1.36 | +25.0% | -253.6M |
| 2023 | 306.1M | +18.4% | -341.4M | -111.5% | -1.82 | -15.7% | -298.4M |
| 2022 | 258.5M | — | -320.8M | -124.1% | -1.57 | — | -328M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 02 Oct 2026 | 28.72 | 28.97 | 28.07 | 28.30 | -0.18% | 3,204,200 | |
| 01 Oct 2026 | 30.60 | 30.96 | 28.29 | 28.35 | -7.44% | 4,406,600 | |
| 30 Sep 2026 | 31.40 | 32.04 | 30.60 | 30.63 | -2.92% | 2,928,800 | |
| 29 Sep 2026 | 31.64 | 32.33 | 30.82 | 31.55 | -0.63% | 3,713,800 | |
| 28 Sep 2026 | 31.73 | 32.09 | 30.88 | 31.75 | -0.72% | 3,938,600 | |
| 25 Sep 2026 | 32.65 | 32.77 | 31.58 | 31.98 | -0.90% | 2,919,200 | |
| 24 Sep 2026 | 31.34 | 32.40 | 30.91 | 32.27 | +1.96% | 5,982,300 | |
| 23 Sep 2026 | 31.12 | 32.89 | 31.10 | 31.65 | +0.57% | 4,359,700 | |
| 22 Sep 2026 | 31.55 | 32.36 | 31.33 | 31.47 | +2.68% | 5,958,800 | |
| 21 Sep 2026 | 30.23 | 30.71 | 29.97 | 30.65 | +2.23% | 6,141,700 | |
| 18 Sep 2026 | 30.29 | 30.99 | 29.69 | 29.98 | -3.04% | 14,722,900 | |
| 17 Sep 2026 | 28.59 | 31.36 | 28.53 | 30.92 | +9.61% | 7,659,600 | |
| 16 Sep 2026 | 28.16 | 29.08 | 27.91 | 28.21 | -1.02% | 4,302,500 | |
| 15 Sep 2026 | 25.80 | 28.67 | 25.80 | 28.50 | +9.40% | 8,839,000 | |
| 14 Sep 2026 | 24.24 | 26.18 | 24.05 | 26.05 | +7.03% | 3,641,900 | |
| 11 Sep 2026 | 24.16 | 24.67 | 24.09 | 24.34 | +1.25% | 1,822,900 | |
| 10 Sep 2026 | 23.20 | 24.68 | 23.20 | 24.04 | +0.04% | 2,629,100 | |
| 09 Sep 2026 | 24.00 | 24.96 | 23.95 | 24.03 | -3.18% | 3,146,800 | |
| 08 Sep 2026 | 25.03 | 25.68 | 24.74 | 24.82 | -1.00% | 4,584,100 | |
| 04 Sep 2026 | 24.88 | 25.14 | 24.47 | 25.07 | -0.99% | 4,711,200 | |
| 03 Sep 2026 | 24.94 | 25.34 | 23.62 | 25.32 | +2.10% | 6,431,600 | |
| 02 Sep 2026 | 25.13 | 25.62 | 24.50 | 24.80 | +0.08% | 5,487,800 | |
| 01 Sep 2026 | 25.60 | 25.62 | 24.55 | 24.78 | -2.79% | 4,027,400 | |
| 31 Aug 2026 | 25.35 | 25.56 | 24.48 | 25.49 | -0.55% | 5,867,500 | |
| 28 Aug 2026 | 26.15 | 26.75 | 25.47 | 25.63 | -2.84% | 3,834,500 |
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- TD Cowen Maintains Buy on Caris Life Sciences, Raises Price Target to $38 (opens in a new tab) Benzinga · 05 Nov 2026 16:27
- Caris Life (CAI) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 05 Nov 2026 15:45
- 14% Below Fair Value? Caris Life Sciences (CAI) On Raised 2026 Guidance (opens in a new tab) Simply Wall St. · 05 Nov 2026 09:13
- BTIG Reiterates Buy on Caris Life Sciences, Maintains $38 Price Target (opens in a new tab) Benzinga · 05 Nov 2026 07:06
- Caris Life Sciences Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 05 Nov 2026 01:14
- Caris Life Sciences (NASDAQ:CAI) Slides After Q3 Beat as Valuation Expectations Reset (opens in a new tab) ChartMill · 04 Nov 2026 23:15
- Caris Life Sciences,?Inc. (CAI) Q3 Earnings and Revenues Top Estimates (opens in a new tab) Zacks · 04 Nov 2026 21:50
- Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 04 Nov 2026 21:44
- Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance (opens in a new tab) 04 Nov 2026 21:05
- Caris Life Sciences Q3 2026 Earnings Call Transcript (opens in a new tab) Benzinga · 04 Nov 2026 19:07
- Caris Life Sciences Raises FY2026 Sales Guidance from $1.030B-$1.040B to $1.040B-$1.050B vs $1.030B Est (opens in a new tab) Benzinga · 04 Nov 2026 17:28
- Caris Life Sciences Q3 EPS $0.05 Beats $0.04 Estimate, Sales $275.358M Beat $255.363M Estimate (opens in a new tab) Benzinga · 04 Nov 2026 17:12
- Analysts Estimate Caris Life Sciences,?Inc. (CAI) to Report a Decline in Earnings: What to Look Out for (opens in a new tab) Zacks · 28 Oct 2026 13:00
- IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months (opens in a new tab) Investor's Business Daily · 02 Oct 2026 20:02
- Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look (opens in a new tab) Investor's Business Daily · 22 Sep 2026 19:01
Headlines link to the original articles of the publishers shown; NowoTrade does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 26.03 USD
- Market cap
- 7.2B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 11.1 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 9.6 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 7.5 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 10.0 / 10 |
|
- Score capped at 60: free cash flow was negative in two of the last three years
- Thin interest cover: operating profit is only 0.8× the interest
- The last full year was a loss
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A). Warnings take 12 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio.
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 15.2× | Fair | 31.09× |
| P/E (forward) | 67.58× | Weak | 14.98× |
| Price / book | 11.31× | Weak | 3.94× |
| Price / sales | 6.9× | Weak | 3.37× |
| EV / EBITDA | 44.08× | Weak | 12.96× |
| Free cash flow yield | -0.4% | Weak | 2.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 69.3% | Good | 59.2% |
| Operating margin | 7% | Weak | 7.4% |
| Net margin | 9.2% | Fair | 3.4% |
| Return on equity | 17.2% | Good | 5.7% |
| Return on assets | 7.8% | Good | 3.6% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 46.5% | Good | 10.8% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.72× | Good | 0.46× |
| Net debt / EBITDA | -1.87× | Good | 1.5× |
| Interest cover | 0.79× | Weak | 3.26× |
| Current ratio | 6.72× | Good | 2.35× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Follow CAI and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.